Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Recruiting

Phase 1

Phase 2

RAS(ON) Inhibitors & IvonescimabStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Sponsor:

Revolution Medicines, Inc.

Code:

NCT07397338

Conditions

Advanced Solid Tumors

Metastatic Solid Tumors

Non-small Cell Lung Cancer (NSCLC)

NSCLC

Colorectal Cancer (CRC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daraxonrasib

Elironrasib

Zoldonrasib

Ivonescimab

Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-10. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2026-02-09.